Hemab Therapeutics Holdings, Inc. Common Stock (COAG) — Defensive Interval Ratio
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) has a Defensive Interval Ratio of 3333 days as of December 2025. Defensive assets of $97.51 Million (cash $-, short-term investments $97.51 Million, receivables $-) cover 3333 days of daily cash needs of $29.25K/day. See Hemab Therapeutics Holdings, Inc. Common current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Defensive Interval Ratio
Defensive Assets
Daily Cash Need
Current Liabilities
Hemab Therapeutics Holdings, Inc. Common Stock Defensive Interval Ratio (2024–2025)
This chart shows how Hemab Therapeutics Holdings, Inc. Common Stock's Defensive Interval Ratio has evolved across 2 annual periods from 2024 to 2025. As of December 2025, the ratio stands at 3333 days, meaning defensive assets of $97.51 Million can fund 3333 days of operations without new revenue. See how leveraged is Hemab Therapeutics Holdings, Inc. Common's balance sheet to measure how much of total assets are equity-financed.
Annual Defensive Interval Ratio for Hemab Therapeutics Holdings, Inc. Common Stock (2024–2025)
The table below presents the year-by-year Defensive Interval Ratio for Hemab Therapeutics Holdings, Inc. Common Stock from 2024 to 2025, covering 2 annual filings. Each row shows defensive assets, daily cash need, the DIR in days, and the change in days compared to the prior year. For live market cap and the full company financial profile, see COAG stock market capitalisation.
| Year | DIR (days) | Defensive Assets (USD) | Daily Cash Need | Cash | ST Investments | Change (days) |
|---|---|---|---|---|---|---|
| 2025 | 3333 days | $97.51 Million | $29.25K/day | $- | $97.51 Million | ▲ +2574 days |
| 2024 | 760 days | $13.92 Million | $18.32K/day | $- | $13.92 Million | — |